E. M. Adang

451 total citations
12 papers, 316 citations indexed

About

E. M. Adang is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, E. M. Adang has authored 12 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 5 papers in Cancer Research. Recurrent topics in E. M. Adang's work include Breast Cancer Treatment Studies (5 papers), Genetic factors in colorectal cancer (4 papers) and Colorectal Cancer Screening and Detection (3 papers). E. M. Adang is often cited by papers focused on Breast Cancer Treatment Studies (5 papers), Genetic factors in colorectal cancer (4 papers) and Colorectal Cancer Screening and Detection (3 papers). E. M. Adang collaborates with scholars based in Netherlands, Taiwan and Poland. E. M. Adang's co-authors include Soeters Pb, Mia L. van der Kop, J.W.M. Greve, Wim G. van Gemert, P.B. Soeters, Nicoline Hoogerbrugge, J. Han van Krieken, F. M. Nagengast, Johan L. Severens and Hans F. A. Vasen and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Clinical Nutrition and Cancer Research.

In The Last Decade

E. M. Adang

11 papers receiving 297 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. M. Adang Netherlands	8	178	116	94	77	73	12	316
Florence Mary France	10	185 1.0×	51 0.4×	133 1.4×	14 0.2×	23 0.3×	28	348
Giovanna Berardi Italy	12	360 2.0×	15 0.1×	67 0.7×	31 0.4×	21 0.3×	40	428
Sertaç Ata Güler Türkiye	8	109 0.6×	62 0.5×	102 1.1×	8 0.1×	55 0.8×	39	262
Bakr Bin Sadiq Saudi Arabia	8	39 0.2×	17 0.1×	98 1.0×	48 0.6×	17 0.2×	10	340
Michelle M. Fennessy United States	7	30 0.2×	36 0.3×	116 1.2×	3 0.0×	132 1.8×	14	299
A Iuppa Italy	8	142 0.8×	9 0.1×	18 0.2×	30 0.4×	5 0.1×	14	205
Catherine Tuppo United States	7	165 0.9×	29 0.3×	279 3.0×	6 0.1×	35 0.5×	10	329
Henry Sue‐Ling United Kingdom	9	386 2.2×	24 0.2×	37 0.4×	28 0.4×	8 0.1×	11	488
Talar Tatarian United States	10	192 1.1×	43 0.4×	48 0.5×	8 0.1×	33 0.5×	28	282
Nasreen Al-Sayed Bahrain	6	71 0.4×	34 0.3×	9 0.1×	2 0.0×	75 1.0×	12	287

Countries citing papers authored by E. M. Adang

Since Specialization

Citations

This map shows the geographic impact of E. M. Adang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. M. Adang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. M. Adang more than expected).

Fields of papers citing papers by E. M. Adang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. M. Adang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. M. Adang. The network helps show where E. M. Adang may publish in the future.

Co-authorship network of co-authors of E. M. Adang

This figure shows the co-authorship network connecting the top 25 collaborators of E. M. Adang. A scholar is included among the top collaborators of E. M. Adang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. M. Adang. E. M. Adang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Adang, E. M., et al.. (2022). CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). American Heart Journal. 254. 141–148. 8 indexed citations

2.

Mensenkamp, Arjen R., et al.. (2014). Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. Annals of Oncology. 25(10). 2001–2007. 21 indexed citations

3.

Tjan‐Heijnen, Vivianne C. G., Manon J. Pepels, Mintsje de Boer, et al.. (2009). Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR study. Journal of Clinical Oncology. 27(18_suppl). CRA506–CRA506. 10 indexed citations

4.

Boer, Maaike de, PJ van Diest, E. M. Adang, et al.. (2009). Micrometastases and isolated tumor cells: relevant and robust or rubbish? (MIRROR): preliminary results of the MIRROR study from the Dutch breast cancer trialists' group (BOOG).. Cancer Research. 69(2_Supplement). 23–23. 9 indexed citations

5.

Diest, Paul van, et al.. (2009). Isolated Tumor Cells in Axillary Lymph Nodes of Breast Cancer Patients: Differential Prognostic Impact of Single Tumor Cell(s) Versus Tumor Cell Clusters, and Microanatomic Location. New Results from the Dutch MIRROR Study.. Cancer Research. 69(24_Supplement). 306–306.

6.

Tjan‐Heijnen, Vivianne C. G., Manon J. Pepels, Mintsje de Boer, et al.. (2009). Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR study. Journal of Clinical Oncology. 27(15_suppl). CRA506–CRA506. 24 indexed citations

7.

Tjan‐Heijnen, Vivianne C. G., Manon J. Pepels, Mintsje de Boer, et al.. (2009). Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR study. Journal of Clinical Oncology. 27(18S). CRA506–CRA506. 4 indexed citations

8.

Nagengast, F. M., et al.. (2006). Optimizing the detection of hereditary non-polyposis colorectal cancer: An update. Scandinavian Journal of Gastroenterology. 41(sup243). 146–152. 2 indexed citations

9.

Kievit, Wietske, F.M. Nagengast, E. M. Adang, et al.. (2005). [More hereditary intestinal cancer can be detected if patients with colorectal carcinoma that are selected by the pathologist are examined for microsatellite instability].. PubMed. 149(32). 1792–8. 5 indexed citations

10.

Kievit, Wietske, E. M. Adang, Johan L. Severens, et al.. (2004). Cost effectiveness of a new strategy to identify HNPCC patients. Gut. 54(1). 97–102. 69 indexed citations

11.

Gemert, Wim G. van, et al.. (1999). A Prospective Cost-Effectiveness Analysis of Vertical Banded Gastroplasty for the Treatment of Morbid Obesity. Obesity Surgery. 9(5). 484–491. 64 indexed citations

12.

Adang, E. M., et al.. (1998). Quality of life assessment of morbidly obese patients: effect of weight-reducing surgery. American Journal of Clinical Nutrition. 67(2). 197–201. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact